Business
EVIO Inc. Retires Convertible Debt
EVIO Inc. Retires Convertible Debt.
About this update from Evio, Inc.
[{"type":"text","content":"\n\n\n\nEVIO Inc. Retires Convertible Debt\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nEVIO Inc. Retires Convertible Debt\nCanada NewsWire\nBEND, Ore., June 25, 2018\n\n\n\nCompany continues to strengthen its balance sheet in conjunction with execution of North American expansion\n\n\n\nBEND, Ore., June 25, 2018 /CNW/ -- EVIO Inc. (OTCQB: EVIO) (\"EVIO\" or \"the Company\"), a leading provider of cannabis testing and scientific research for the regulated cannabis industry, announced today that floorless convertible notes issued pursuant to the company's 2017 debt offerings, which was raised to facilitate key acquisitions and expansion, have been fully retired and the Company has no further obligations under the notes of those offerings.  \n\n\n \n \n\n \n\"We're pleased to have these convertible debentures fully retired as we continue to strengthen EVIO's balance sheet and focus on improving shareholder value,\" said William Waldrop, CEO of EVIO. \"As communicated with our shareholders last fall, the company is committed to using traditional types of financing to support our continued growth.  With California's additional mandated testing requirements coming into full force on July 1, and our continued expansion into growing marketplaces, we believe EVIO is well positioned to deliver growth in 2018 and beyond.\"\n\nAbout EVIO Inc. (OTCQB: EVIO)EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply.  The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.For more information, visit www.eviolabs.com.\n\nSafe Harbor StatementAny statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Statements may contain certain forward-looking statements...